Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab [0.03%]
淋巴细胞单核细胞比值可预测Durvalumab联合Tremelimumab治疗肝癌患者的生存率
Tomomitsu Matono,Toshifumi Tada,Atsushi Hiraoka et al.
Tomomitsu Matono et al.
Background and aims: This multicenter retrospective study in Japan aimed to investigate the prognostic significance of lymphocyte-to-monocyte ratio (LMR) in patients with unresectable hepatocellular carcinoma (HCC) treate...
Early Prediction of Hepatic Decompensation in Cirrhosis Using Optimised XGBoost Models at the Initial Outpatient Hepatology Visit [0.03%]
基于优化XGboost模型在首次肝病专科门诊预测失代偿期肝硬化的发生
Micah Grubert Van Iderstine,Sem Perez,Gregory S Jackson et al.
Micah Grubert Van Iderstine et al.
Background and aims: Hepatic decompensation represents a critical transition in cirrhosis, leading to increased morbidity, mortality and healthcare utilisation. Identifying patients at risk of decompensation remains a cli...
Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD [0.03%]
激素替代疗法对围绝经期MASLD患者肝脏和心血管代谢结局的影响
Alex E Henney,Jo Wilson,David R Riley et al.
Alex E Henney et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction,...
Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort [0.03%]
国际多中心现实世界肝癌治愈患者的长期死亡率研究
Fanpu Ji,Sally Tran,Hidenori Toyoda et al.
Fanpu Ji et al.
Background & aims: Direct-acting antiviral agents (DAA)-mediated HCV cure correlates with better outcomes, but there are insufficient data on detailed mortality-related risk factors after cure. This study sought to clarif...
Redefining Obesity Improves the Identification of Advanced Fibrosis Among MAFLD/MASLD Patients [0.03%]
重新定义肥胖可改善非酒精性脂肪肝病患者晚期纤维化的识别率
Alaa M Mostafa,Yasser Fouad,Mohammed Eslam
Alaa M Mostafa
Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC [0.03%]
sintilimab联合ibi305与pd-1抑制剂联合tkis在联合tace治疗不可切除肝癌中的疗效和安全性比较
Houxiang Ya,Kai Wang,Huixia Qin et al.
Houxiang Ya et al.
Background: Systemic therapy combined with transcatheter arterial chemoembolization (TACE) is the main treatment strategy for patients with unresectable hepatocellular carcinoma (uHCC). Nevertheless, there are currently f...
Letter to the Editor: Interpreting the Clinical Applicability of SGLT-2 Inhibitors in MASH-Related Cirrhosis [0.03%]
读者来信：SGLT-2抑制剂在MASH相关性肝硬化中临床应用的解读
Binqi Wang,Chan Gao,Juan Jin et al.
Binqi Wang et al.
Prevalence and Spectrum of Chronic Liver Disease Among Patients Seeking Health Care in Ghana [0.03%]
在加纳求医患者中的慢性肝病患病率和疾病谱
Felix Lehmann,Alexander Killer,Sarah Wels et al.
Felix Lehmann et al.
Background: Chronic liver diseases (CLD) leading to liver fibrosis and cirrhosis are a major cause of morbidity and mortality in sub-Saharan Africa and pose a significant burden on its health care systems. We aimed to elu...